

Thomas O. Forslund, Director

Governor Matthew H. Mead

## FAX

To:	VFC/WyVIP Primary and Secondary Vaccine Coordinators				
From:	Jude Serrano, Vaccine Program Specialist	Fax:	307-777-3615	Phone:	307-777-2413
Re:	<b>Pediarix® Supply Update</b>	Date:	April 25, 2013	Pages:	2

### **PEDIARIX® Supply Update**

The VFC Program has been notified that PEDIARIX® will be allocated to all grantees. Effective immediately, the Program will only be allotted 70% of the normal monthly order quantity. Pentacel® vaccine remains unavailable.

#### **What does an allocation mean for providers?**

- Provider orders for PEDIARIX® are likely to be cut during this time.
- Providers who order PEDIARIX® will see a delay in the processing of their orders as the Program must wait until all orders are submitted before applying the allocations and identifying cuts.
- Because of the limited supply, Providers may run out of PEDIARIX®.
  - Once that occurs, it is recommended that Providers use single antigen vaccines for DTaP, IPV and Hepatitis B. Providers should continue to follow the ACIP recommended childhood immunization schedule for the single antigen vaccines.

The VFC Program appreciates the patience of Providers as we work through this situation. Allocations can be very challenging, but it is our desire to create an equitable process in an effort to distribute vaccines in the most effective way.

Enclosed is a statement from GlaxoSmithKline regarding the supply of PEDIARIX®. Questions may be directed to the Immunization Unit at 307-777-8503.

**IMPORTANT WARNING:** This message is intended for the use of the person or entity to which it is addressed and may contain privileged and confidential information, the disclosure of which is governed by applicable law.

If you are not the intended recipient, employee or agent responsible to deliver it to the intended recipient, you are hereby notified any disclosure, copying, distribution or action taken in reliance on these documents is **Strictly Prohibited**. If you have received this message in error, please notify the sender immediately to arrange for return or destruction of these documents.

The attached documents may contain Protected Health Information (PHI). PHI is personal and sensitive information related to a person's health care. It is being faxed to you after appropriate authorization from the patient or under circumstances not requiring patient authorization. You, the recipient, are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure without additional patient consent or as permitted by law is prohibited. You may be subject to penalties described in federal and state law for unauthorized re-disclosure or failure to maintain confidentiality.

Public Health Division • Community Health Section • Immunization Unit  
6101 Yellowstone Road, Suite 420 • Cheyenne, WY 82002

WEB Page: [www.immunizewyoming.com](http://www.immunizewyoming.com)

**Toll Free 1-866-571-0944 • Main Number (307) 777-7952 • FAX (307) 777-3615**



**GlaxoSmithKline**  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel. 919 483 2100  
www.gsk.com

April 2013

**Subject: PEDIARIX® [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] Supply Update**

Dear Healthcare Provider:

On behalf of GlaxoSmithKline (GSK) Vaccines, I would like to take this opportunity to make you aware of the steps GSK is taking with regard to supply for its combination diphtheria, tetanus, and acellular pertussis (DTaP) vaccine, PEDIARIX, in light of ongoing market supply constraints on combination DTaP vaccines.

In response to the shortage of combination DTaP vaccine from another supplier to the marketplace beginning in April 2012, GSK took steps to meet increased demand for its combination DTaP vaccine by increasing production.

Having recently become aware that the current marketplace shortage is now expected to continue into the summer of 2013, GSK will continue its efforts to increase production of PEDIARIX to help meet market demand. However, due to the long lead time required to manufacture vaccines, the additional supply of PEDIARIX is not anticipated to be available until Q3 2013.

Unfortunately, due to the continued shortage of combination DTaP vaccine, GSK now expects to be able to cover only a portion of the continued shortage with PEDIARIX. To help ensure that some quantity of combination DTaP vaccine remains available to as many providers as possible, GSK will institute allocations of PEDIARIX until September 2013 with the intention of removing these allocations once DTaP combination vaccine availability increases.

Please be aware that GSK currently expects to have sufficient supply of INFANRIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) to cover the potential shortage of PEDIARIX that may result from our allocation efforts.

GSK shares your goal of vaccinating all appropriate infants against diphtheria, tetanus, and pertussis. I want to extend my sincerest apologies for any frustration or disruption to your practices and facilities this short-term allocation of PEDIARIX may cause.

Please do not hesitate to contact GlaxoSmithKline with any further questions or concerns. You may reach out to us at 1.866.GSK.VACC (1.866.475.8222) or contact your GlaxoSmithKline Vaccines Representative today.

Sincerely,

A handwritten signature in black ink that reads "Mike Thomas".

Michael F. Thomas  
US Vaccines Business Unit Head